This is topic CTIC - received "fast track" designation from FDA in forum Hot Stocks Free for All ! at Allstocks.com's Bulletin Board.


To visit this topic, use this URL:
http://www.allstocks.com/stockmessageboard/ubb/ultimatebb.php/ubb/get_topic/f/2/t/014016.html

Posted by netguy81 on :
 
CTIC - Cell Therapeutics

Cell Therapeutics received "fast track" designation from the U.S. Food and Drug Administration for the treatment of certain types of cancer in women with a specific type of lung cancer.

http://biz.yahoo.com/bizj/070411/1445306.html?.v=1

Trading on Huge Volume today and it might go up for the next few days.

Related Articles
http://www.marketwatch.com/News/Story/Story.aspx?guid=%7bC7C99B41-4FE1-4AAA-8EB4 -56F31F0D809C%7d&siteid=yhoo&dist=yhoo

http://www.thestreet.com/_yahoo/newsanalysis/winnershealth/10349665.html?cm_ven= YAHOO&cm_cat=FREE&cm_ite=NA

Do your own DD and invest ... this might be a long term hold !!
 
Posted by Livinonklendathu on :
 
1 for 4 R/S and A/S increase on 4-15.

http://sec.freeedgar.com/resultsFilings.asp?ID=5460

http://www.stockhouse.com/news/news.asp?newsid=5040433&tick=CTIC
 
Posted by netguy81 on :
 
thanks a lot livinon ... i didnt catch that news at all ...

so they are going to do reverse split and then increase the A/S ... ???
 
Posted by Livinonklendathu on :
 
Exactly:


Apr 11, 2007 (M2 EQUITYBITES via COMTEX News Network) --
Biopharmaceutical company Cell Therapeutics Inc (Nasdaq and MTAX: CTIC) announced on 10 April that its shareholders have approved the proposal to increase the number of authorised shares from 210m to 410m and to increase the number of authorised common shares from 200m to 400m.

Cell Therapeutics said that as of 15 April, the expected effective date of the one-for-four reverse stock split of common shares, the authorised common shares will total 100m with approximately 40m shares issued and outstanding.
 
Posted by Livinonklendathu on :
 
Now CTICD
 


© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2